INSULET Business Summary

Insulet Corporation (PODD) operates a high-growth medical device business model centered on the Omnipod product platform, generating recurring revenue through the sale of disposable, tubeless insulin pods. The company’s revenue is primarily derived from two segments: Omnipod (U.S. and International), which accounts for over 98% of total sales, and a contracting Drug Delivery segment focused on non-insulin applications. As of February 2026, Insulet has sustained a decade of 20%+ constant currency growth, bolstered by the global rollout of the Omnipod 5 Automated Insulin Delivery (AID) system and its recent expansion into the Type 2 diabetes market. In the competitive landscape, Insulet holds a unique leadership position as the primary provider of tubeless technology, competing directly with Tandem Diabetes Care, Medtronic, and the integrated sensor-pump ecosystems of DexCom and Abbott Laboratories. Established in 2000 by John Brooks III, Amparo Diaz, and Duane DeSisto, Insulet is currently led by President and CEO Ashley A. McEvoy, the former Worldwide Chairman of MedTech at Johnson & Johnson. The leadership team includes CFO Flavia Pease, previously of Charles River Laboratories, and CTO Amit Guliani, who brings over 25 years of engineering experience from Sysco and Stryker. The company’s board of directors, chaired by Timothy John Scannell, features prominent industry figures such as Robert L. Huffines and Alcon CFO Timothy Stonesifer. Insulet maintains a robust institutional investor base, with major positions held by The Vanguard Group, BlackRock, and FMR LLC, supporting its current $1 billion R&D commitment toward the Omnipod 6 platform and entry into major Asian markets.